Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>To examine multiple of the median (MoM) levels of serum free β‐hCG and PAPP‐A in a large series of pregnancies with a vanishing twin, determine the association of these levels with the interval between embryonic death and blood sampling and develop a model that would allow incorporation of these metabolites in first‐trimester combined screening for trisomies.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>This was a retrospective study comparing maternal serum free β‐hCG and PAPP‐A levels at 11‐13 weeks' gestation in 528 dichorionic pregnancies with vanishing twins, including 194 (36.7%) with an empty gestational sac and 334 (63.3%) with a dead embryo, with levels in 5,280 normal singleton pregnancies matched for method of conception and date of examination. In the vanishing twins marker levels were examined in relation to the estimated time between embryonic death and maternal blood sampling.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>The main findings were: first, in vanishing twins the median free ß‐hCG MoM was not significantly different from that of normal singleton pregnancies (1.000, 95% CI 0.985 ‐ 1.0156, versus 0.995, 95% CI 0.948 ‐ 1.044; p= 0.849), second, PAPP‐A MoM was higher in vanishing twins than in normal singleton pregnancies (1.000, 95% CI 0.985 ‐ 1.015), both in the group with an empty gestational sac (1.165, 95% CI 1.080 ‐ 1.256; p=0.0001), and in those with a dead embryo (1.175, 95%CI 1.105 ‐1.249; p<0.0001), third, in vanishing twins with a dead embryo PAPP‐A MoM was inversely related to the interval between estimated gestational age at embryonic demise and blood sampling (p<0001), fourth, in first‐trimester screening for trisomy 21 in singleton pregnancies the estimated detection rate, at 5% false positive rate, was 82% in screening by a combination of maternal age and fetal NT and this increased to 86% with the addition of serum free ß‐hCG and then to 91% with the addition of serum PAPP‐A, and fifth, similar performance of screening can be achieved in vanishing twins, provided the appropriate adjustments are made in the level of PAPP‐A for the interval between estimated gestational age at embryonic demise and blood sampling.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>First‐trimester screening for trisomies in vanishing twins should rely on a combination of maternal age, fetal nuchal translucency thickness and serum free β‐hCG, as in a singleton pregnancy, without the use of serum PAPP‐A. Alternatively, PAPP‐A can be included but only after appropriate adjustment for the interval between the estimated gestational age at fetal demise and blood sampling.</p><p>This article is protected by copyright. All rights reserved.</p></section>

First‐trimester screening for trisomies in pregnancies with vanishing twin

Noninvasive Prenatal Testing of Trisomies 21 and 18 by Massively Parallel Sequencing of Maternal Plasma DNA in Twin Pregnancies.

The Effect of Vanishing Twin on First- and Second-Trimester Maternal Serum Markers and Nuchal Translucency: A Multicenter Prospective Cohort Study

Serum marker truncation limits in first trimester antenatal screening for trisomy 18

Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks

[First-trimester screening for trisomies 18 and 13 with the combined use of the risk algorithms for trisomy 21, 18 and 13]

Cell‐free DNA test for fetal chromosomal abnormalities in multiple pregnancies

Screening for trisomies by cfDNA testing of maternal blood in twin pregnancy: update of The Fetal Medicine Foundation results and meta‐analysis

Non‐invasive prenatal testing (NIPT) in twin pregnancies affected by early single fetal demise: A systematic review of NIPT and vanishing twins

The Value of Combined Detailed First-Trimester Ultrasound–biochemical Analysis for Screening Fetal Aneuploidy in the Era of Non-Invasive Prenatal Testing

First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A

Comparison of three first trimester screening algorithms for trisomy 21 with and without adjustment for maternal characteristics

First-Trimester Combined Screening is Effective for the Detection of Unbalanced Chromosomal Translocations at 11 to 12 Weeks of Gestation

Analysis of triple test results in 27 cases of twin pregnancies

Comparison of triple-risk assessment of fetal trisomy 21 including total human choriogonadotropin (hCG) or its free beta-subunit (free beta hCG)

First-Trimester Ultrasound Screening in Routine Obstetric Practice

[Study on Several Ultrasound Markers Combined Maternal Serum Biochemical Markers to Screen Fetal Chromosomal Aneuploidy at 11 to 13(+)6 Weeks of Gestation].

Serial first- and second-trimester Down's syndrome screening tests among IVF-versus naturally-conceived singletons

A retrospective evaluation of second-trimester serum screening for fetal trisomy 18: experience of two laboratories

Cell-Free DNA Screening for Trisomy 21 in Twin Pregnancy: A Large Multicenter Cohort Study

Performance of cell‐free DNA testing for common fetal trisomies in triplet pregnancies